What is the 13F Pro Quality Score for KURA?

13F Pro ranks Kura Oncology, Inc. (KURA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KURA's current score at https://13fpro.ai/research/KURA (free sign-up required for the full ranking).

Which hedge funds own the most KURA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of KURA include BlackRock,, SUVRETTA CAPITAL MANAGEMENT,, BVF /IL. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/KURA as soon as new 13F filings post.

Where does 13F Pro source KURA data?

All Kura Oncology, Inc. fundamentals and ownership data come directly from SEC EDGAR. Kura Oncology, Inc. files with the SEC under CIK 1422143. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KURA in?

Kura Oncology, Inc. (KURA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KURA research updated on 13F Pro?

KURA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Kura Oncology, Inc.(KURA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1422143 KURA stock profile & AI dashboard →

13F Pro Quality Score

9.1/100

Rank #2,819 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

4.3/100

Profitability

3.9/100

Balance Sheet

5.5/100

Earnings Quality

30.0/100

Free Cash Flow

3.7/100

Institutional Flow

46.1/100

Revenue Scale

13.8/100

Dilution Risk

4.4/100

KURA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Kura Oncology, Inc. (KURA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KURA at 9.1/100 on a 32-signal composite quality model, placing it at rank #2,819 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (3.7) and profitability (3.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Kura Oncology, Inc. reports quarterly revenue of $18.3M, net income of $-73.3M, free cash flow of $-86.0M. Top institutional holders of KURA by reported 13-F value include BlackRock,, SUVRETTA CAPITAL MANAGEMENT,, BVF /IL, based on the most recent SEC filings. KURA trades on the Nasdaq exchange and files with the SEC under CIK 1422143. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KURA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kura Oncology, Inc. directly from SEC EDGAR. Kura Oncology, Inc.'s 13F Pro composite quality score has ranged between 9 and 44 since 2025, currently 9.1 — a declining long-term trajectory across 12 quarterly and live scoring snapshots.

Revenue

Q1 2026

$18.3M

Net Income

Q1 2026

$-73.3M

Free Cash Flow

Q1 2026

$-86.0M

D/E Ratio

Q1 2026

0.09

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$67.5MFY 2025

FY19 —FY21 —FY22 —FY25 $67.5M

Net Income

-105.1% YoY

$-278.7MFY 2025

FY19 $-63.1MFY21 $-130.5MFY22 $-135.8MFY25 $-278.7M

Operating Income

-117.1% YoY

$-303.6MFY 2025

FY19 —FY21 —FY22 $-139.9MFY25 $-303.6M

EPS (Diluted)

-56.7% YoY

$-3.18FY 2025

FY19 —FY21 $-1.97FY22 $-2.03FY25 $-3.18

Total Assets

+61.8% YoY

$738.4MFY 2025

FY19 $242.0MFY21 $534.1MFY22 $456.3MFY25 $738.4M

Total Debt

+6.0% YoY

$9.7MFY 2025

FY19 $7.5MFY21 —FY22 $9.2MFY25 $9.7M

Op. Cash Flow

+41.8% YoY

$-64.1MFY 2025

FY19 $-54.8MFY21 $-104.6MFY22 $-110.1MFY25 $-64.1M

Metric	FY 2025	FY 2022	FY 2021	FY 2019	FY 2018	FY 2015
Revenue	$67.5M	—	—	—	—	—
Net Income	$-278.7M -105.1%	$-135.8M -4.1%	$-130.5M -106.6%	$-63.1M -4.5%	$-60.4M -167.2%	$-22.6M
Operating Income	$-303.6M -117.1%	$-139.9M	—	—	—	—
EPS (Diluted)	$-3.18 -56.7%	$-2.03 -3.0%	$-1.97	—	—	—
Total Assets	$738.4M +61.8%	$456.3M -14.6%	$534.1M +120.7%	$242.0M +32.7%	$182.4M +109.0%	$87.3M
Total Debt	$9.7M +6.0%	$9.2M	—	$7.5M +0.0%	$7.5M	—
Operating Cash Flow	$-64.1M +41.8%	$-110.1M -5.3%	$-104.6M -90.9%	$-54.8M -12.5%	$-48.7M	—

AI Insight: KURA Ratio Trends

KURA remains deeply unprofitable with deteriorating returns; Q4 2025 ROE plunged to -186.1%, the worst in the dataset.

• ROE collapsed from -18.6% in Q4 2024 to -186.1% in Q4 2025, signaling severe shareholder value destruction.

• ROIC hit -92.2% in Q2 2025, indicating invested capital is generating substantial losses with no recovery trend evident.

• Leverage (D/E) edged up from 0.02–0.03 range in 2024 to 0.09 in TTM 2026, though still modest in absolute terms.

⚠ Consistent negative ROA around -30% to -45% across all recent quarters suggests operational losses are structural, not cyclical.

⚠ Operating and net profit margins unavailable; unable to assess cost structure or whether burn is R&D-driven or operational inefficiency.

Get alerted when KURA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Kura Oncology, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KURA

BlackRock, Inc.
$78.4M9,637,531 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$69.7M8,575,422 sh
BVF INC/IL
$68.7M8,445,769 sh
STATE STREET CORP
$36.7M4,511,891 sh
VANGUARD CAPITAL MANAGEMENT LLC
$30.8M3,785,685 sh
ARMISTICE CAPITAL, LLC
$30.4M3,736,000 sh
Prosight Management, LP
$27.3M3,356,700 sh
Deep Track Capital, LP
$21.5M2,643,542 sh
AQR CAPITAL MANAGEMENT LLC
$17.3M2,124,480 sh
GEODE CAPITAL MANAGEMENT, LLC
$16.5M2,034,276 sh

Fund	Value	Shares
BlackRock, Inc.	$78.4M	9,637,531
SUVRETTA CAPITAL MANAGEMENT, LLC	$69.7M	8,575,422
BVF INC/IL	$68.7M	8,445,769
STATE STREET CORP	$36.7M	4,511,891
VANGUARD CAPITAL MANAGEMENT LLC	$30.8M	3,785,685
ARMISTICE CAPITAL, LLC	$30.4M	3,736,000
Prosight Management, LP	$27.3M	3,356,700
Deep Track Capital, LP	$21.5M	2,643,542
AQR CAPITAL MANAGEMENT LLC	$17.3M	2,124,480
GEODE CAPITAL MANAGEMENT, LLC	$16.5M	2,034,276

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KURA on your watchlist

Track score changes the day Kura Oncology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KURA a good stock to buy?

13F Pro's AI-powered analysis of Kura Oncology, Inc. (KURA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KURA are available on the KURA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own KURA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KURA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kura Oncology, Inc.'s investment landscape.